iCell Gene Therapeutics is developing Chimeric Antigen Receptor (CAR) engineered cells that target multiple types of cancer that are particularly difficult to treat, with very poor prognoses. We create novel CAR constructs and CAR enhancing technologies to improve functional properties and expand applicability of engineered T & NK cells. Our lead project is positioned to be the first CAR to enter clinical study directed against T-cell malignancies. Clinical trials of two additional CARs, targeting B-cell malignancies and Multiple Myeloma (MM), are also to be initiated in 2017:
Our pipeline includes multiple unique, pre-clinically validated, and very promising CARs targeting hematological cancers, non-hematological cancers and autoimmune disorders.
LATEST NEWS AND PUBLICATIONS
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Chen et al., Leukemia 2017
iCell Gene Therapeutics Receives Orphan Drug Designation for CAR-T Targeting Peripheral T-cell Lymphoma (PTCL)
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Chen et al., Oncotarget 2016
Preclinical targeting of human T cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Pinz et al., Leukemia 2016